Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors

BACKGROUND: Nonmetastatic castration-resistant prostate cancer (nmCRPC) is defined as a rising prostate-specific antigen concentration, despite castrate levels of testosterone with ongoing androgen-deprivation therapy or orchiectomy, and no detectable metastases by conventional imaging. Patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Saad, Fred, Bögemann, Martin, Suzuki, Kazuhiro, Shore, Neal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134049/
https://www.ncbi.nlm.nih.gov/pubmed/33558665
http://dx.doi.org/10.1038/s41391-020-00310-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134049/
https://www.ncbi.nlm.nih.gov/pubmed/33558665
http://dx.doi.org/10.1038/s41391-020-00310-3

Ejemplares similares